2021
Wheat oral immunotherapy
Leeds S, Liu EG, Nowak-Wegrzyn A. Wheat oral immunotherapy. Current Opinion In Allergy And Clinical Immunology 2021, 21: 269-277. PMID: 33840798, DOI: 10.1097/aci.0000000000000743.Peer-Reviewed Original ResearchConceptsWheat oral immunotherapyOral immunotherapyMaintenance dosesSevere reactionsFood allergy epidemiologyLow maintenance dosesNonrandomized clinical trialRisk of reactionSustained unresponsivenessSuccessful desensitizationAdjunct therapeuticsFood allergyTrial protocolClinical trialsAllergic reactionsAllergy epidemiologyHuman trialsSafety outcomesHead comparisonAugmenting factorSmall sample sizeTrialsFood modificationImmunotherapyDoses
2016
Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models
Marek E, Momper J, Hines R, Takao C, Gill J, Pravica V, Gaedigk A, Burckart G, Neville K. Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. The Journal Of Pediatric Pharmacology And Therapeutics 2016, 21: 224-32. PMID: 27453700, PMCID: PMC4956330, DOI: 10.5863/1551-6776-21.3.224.Peer-Reviewed Original ResearchValidation cohortPediatric patientsStable international normalized ratioInternational normalized ratioStable warfarin dosesFixed-dose approachActual maintenance doseMaintenance doseMaintenance dosesStandard careMulticenter trialWarfarin dosesNormalized ratioSeparate clinical sitesWarfarin doseIndependent cohortClinical sitesCohortPatientsDose prediction modelDose modelDosesProportion of varianceObserved dosesDose
2013
An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia
McCavit T, Krishnamurti L, Hsu L, Quinn C, Odame I, Alvarez O, Driscoll C, Smith-Whitley K, Rhee S, Wun T, Telen M, Thackray H. An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. Blood 2013, 122: 2206. DOI: 10.1182/blood.v122.21.2206.2206.Peer-Reviewed Original ResearchVaso-occlusive crisisSerious adverse eventsSickle cell anemiaAcute chest syndromeStudy drugPediatric subjectsAdult subjectsMaintenance dosesOpioid useSecondary outcomesMedian timePlacebo-controlled phase 2 trialCell anemiaRed blood cell transfusionPhase 3 clinical trialsStrong efficacy signalBlood cell transfusionPhase 2 studyPhase 2 trialKaplan-Meier methodVisual analog scaleInitial medical evaluationPan-selectin inhibitorAdvisory CommitteeMinimal safety concernsBuprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone
Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain 2013, 154: 1442-1448. PMID: 23707283, PMCID: PMC3770461, DOI: 10.1016/j.pain.2013.05.004.Peer-Reviewed Original ResearchConceptsBUP/NXWithdrawal symptomsChronic painDrug choiceOral oxycodoneMaintenance doseBuprenorphine/naloxone maintenanceOpioid withdrawal symptomsReduction of painPromising therapeutic optionMore withdrawal symptomsLogistic regression analysisSelf-administer oxycodoneMann-Whitney testOxycodone doseOxycodone dosesMaintenance dosesBuprenorphine/Prescription opioidsMore painOxycodone useTherapeutic optionsClinical painInpatient studyOpioid abuse
2010
Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing
Roper N, Storer B, Bona R, Fang M. Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. Journal Of Molecular Diagnostics 2010, 12: 283-291. PMID: 20228265, PMCID: PMC2860463, DOI: 10.2353/jmoldx.2010.090110.Peer-Reviewed Original ResearchConceptsPharmacogenetics-based dosing algorithmDosing algorithmInternational Warfarin Pharmacogenetics ConsortiumPercentage of patientsNarrow therapeutic windowDiverse ethnic populationsMaintenance dosesProspective trialWarfarin dosesWarfarin dosingPrescribed drugsPharmacogenetic testingWarfarin metabolismIWPC algorithmClinical utilityDosing rangeTherapeutic windowWarfarinGenetic testingPatientsGenetic polymorphismsExternal validationEthnic populationsService populationCYP2C9
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply